Type 2 Diabetes

Muthiah Vaduganathan, MD, MPH, discusses how research of the add-on drug class will continue to evolve into 2021.

What's known about at-risk cardiometabolic patient care during the pandemic.

Transplanted hearts are protected by the diabetes drug Metformin, when the recipient is diabetic a study in the Journal of the American College of Cardiology finds.

A discussion with a Brigham and Women's Hospital cardiologist on the research of the add-on cardiometabolic drug class.

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Telehealth tools can identify someone whose symptoms are worsening and connect them to a medical professional.

Physicians and patients should continue treatment with their usual anti-hypertensive or diabetes management therapy, says the European Society of Cardiology (ESC).  There is no evidence that ACEi or ARBs, drugs which upregulate Angiotensin Converting Enzyme (ACE), increase the risk of contracting COVID-19, the society said in a statement published March 13.

Digital tools like electronic health records play an important role in addressing care for patients with chronic health conditions.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

Patients with cardiovascular disease, respiratory disease, cancer and diabetes are at increased risk for contracting COVID-19 and have a worse prognosis, said the American College of Cardiology in a clinical bulletin released March 6.

A new study is diving into differences in long-term outcomes, including remission rates and weight loss, seen among patients undergoing RYGB and SG.

An analysis of 180,000 patients in South Korea is shedding new light on the potential poor oral hygiene can have on a person's risk of diabetes.

Early menopause onset has been linked to increased CVD risk, but a new study from England is examining whether age of onset has a role in worsening risk factors.

With approval, the GLP-1 receptor agonist becomes the first diabetes drug approved for reducing MACE in patients with and without established cardiovascular.

A look back on the biggest discussions of the 29th Annual Cardiovascular Conference in Beaver Creek, CO.

A new analysis is revealing more about how using a patient portal can aid in medication adherence and HbA1c management among diabetics.

Researchers writing in Diabetes Care this month report that empagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2), successfully reduced liver fat content in recent-onset and metabolically well-controlled type 2 diabetes (T2D).

Medicaid expansion under the Patient Protection and Affordable Care Act (ACA) was associated with reduced uninsured rates in the diabetes belt compared with non-belt counties, say researchers writing in Diabetes Care.

New research from the American Stroke Association's International Stroke Conference indicates the presence of diabetic retinopathy was associated with increased stroke risk.

In post-myocardial infarction patients, chronically impaired renal failure and diabetes are both associated with an increased mortality risk, say researchers recently writing in Diabetes Care.

David Lee, MD, of NYU School of Medicine, discusses barbershop initiatives and how they can impact the health care of a community as a whole.

Offspring of severely obese mothers with insulin-treated pregestational diabetes are at an estimated 128% increased risk of being diagnosed with a psychiatric disorder.

A meta-analysis of CREDENCE, DECLARE-TIMI 58, CANVAS, and EMPA-REG OUTCOME trial is revealing more about how SGLT2 inhibition impacts different subgroups of diabetics.

Leading experts on nutrition and diabetes are recommending that patients still continue to follow current nutritional recommendations by the American Diabetes Association and other healthcare and governmental organizations that recommend consuming a diet rich in fruits and vegetables, while limiting red and processed meats.

An oral tablet combining empagliflozin, linagliptin, metformin hydrochloride will soon be available on US markets.

A new analysis of more than 125,000 found no differences in mortality or MACE based on type of insulin used.

The GLP-1 agonist now has indications for the reduction of MACE and the management of A1C in patients with type 2 diabetes.

A pilot study from the University of Warwick found sitagliptin, which is approved for glycemic control in diabetics, could be a promising treatment for reducing miscarriages in women with recurrent pregnancy loss.

The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.